Skip to content

Comparing the effects of Berberine, Curcumine and gonadotropin-releasing hormone agonist (GnRH) on uterine leiomyoma volume

Comparing the effects of Berberine, Curcumine and gonadotropin-releasing hormone agonist (GnRH) on uterine leiomyoma volume , a controlled, randomized clinical trials

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20220201053908N1
Enrollment
102
Registered
2022-02-23
Start date
2022-03-06
Completion date
Unknown
Last updated
2022-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Uterine myoma.

Interventions

Intervention 1: Intervention group: The first group treated with curcumin, each tablet contains 450mg of turmeric rhizome powder and 50mg of turmeric extract, which is standardized based on 5.47mg of

Sponsors

Semnan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: Non-menopausal women between the ages of 18 and 45, who have a myoma larger than 5 cm that have abnormal uterine bleeding, pelvic pain, dysmenorrhea, and a compressive effect. Women with myomas larger than or equal to 5 cm who have other myomas (s) less than 2 cm in size

Exclusion criteria

Exclusion criteria: Women with extra myoma (s) greater than or equal to 2 cm Women with uterine myoma who have been treated with any type of estrogen or progesterone in less than a month and hormonal implants in the last 3 months Women with a history of major medical illness and / or previous drug or surgical treatment of uterine leiomyomas All women with myomas 2-5 cm in size were excluded from the study Patients receiving antihypertensive drugs, beta-blockers and calcium channel blockers, and ACE inhibitors were excluded from the study due to possible drug interactions Patients who develop side effects during the study will be excluded from the study

Design outcomes

Primary

MeasureTime frame
Uterine myoma size. Timepoint: At the beginning of the study and 6 and 12 weeks after starting treatment. Method of measurement: Vaginal ultrasound machine.

Secondary

MeasureTime frame
LH hormon. Timepoint: At the beginning of the study and 12 weeks after treatment. Method of measurement: RIA laboratory method.;FSH hormon. Timepoint: At the beginning of the study and 12 weeks after treatment. Method of measurement: RIA laboratory method.;Estradiol hormon. Timepoint: At the beginning of the study and 12 weeks after treatment. Method of measurement: RIA laboratory method.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactElham saffarieh

Semnan University of Medical Sciences

eli_saffarieh@yahoo.com+98 23 3346 0055

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026